Safety Alerts & Recalls

What does this mean?

This recall for Humira Pen Psoriasis Starter Package was issued at a warehouse/pharmacy level only. The FDA and the manufacturer have determined that any recalled product that may have been dispensed to patients does not pose a significant health risk.

If you have any of the recalled lots of the Humira Pen Psoriasis Starter Package and are concerned, you should consult with your physician or pharmacist. This is also a good reminder that you should confirm the directions with your doctor and pharmacist when starting new medicines.

Recall of Four Lots of Humira Pen Psoriasis Starter Package

Abbott Laboratories has issued a voluntary recall of several lots of Humira (adalimumab) Pen Psoriasis Starter Package with 4 single use prefilled pens of Humira for subcutaneous use only, 40 mg/0.8mL. The following lots and expiration dates (Exp) are being recalled because the some of the Humira Psoriasis Starter Packages may have been mispackaged with the pens placed within the carton in way that does not follow the recommended initial dosing directions: Lot # 70266SP44, Exp SEP 2010

Lot # 74329SP41, Exp JAN 2011

Lot # 74329SP42, Exp JAN 2011

Lot # 74329SP45, Exp JAN 2011

Humira contains the active ingredient adalimumab and is used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, anklyosing spondylitis, Crohn's disease, and psoriasis. Humira is dispensed in several different types of packages. This recall only applies to four specific lots of Humira Pen 40 mg/0.8 mLin the Psoriasis Starter Package.

For more information, please visit: more information here

Source: FDA
Publication Date: 2010-04-02
Last Updated: 2010-04-02

Visit the medication page for the following drugs:

Share your story Share your story! Tell us how MediGuard has helped you or someone you love. Mobile graphic Download the MediGuard Mobile App to manage your prescription and over-the-counter medications, for free. Registration Info Taking multiple medications puts you at risk for possible drug-drug interactions Registration Info Monitor the medical treatment of you and your loved ones.